The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for ...

The consumer-goods company is selling a majority stake in its home-care business to Advent International as it looks to sharpen its focus on core brands. The company reported a second-quarter earnings ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

U.S. stocks appear poised for a positive opening on Friday, as strong earnings from major companies throughout the week have ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...